A case of spontaneously recovering multifocal motor neuropathy with conduction blocks (MMNCB) during anti-TNF alpha therapy for ankylosing spondylitis.
We report the case of a 54-year-old patient affected by ankylosing spondylitis who developed multifocal motor neuropathy with conduction blocks after 8 months of infliximab treatment. TNF alpha antagonist therapy has been associated with the development of both central nervous system and peripheral nervous system disorders, mainly of the demyelinating type. To our knowledge, this seems to be the second reported case of infliximab-related typical multifocal motor neuropathy with conduction blocks in which no other underlying causes of neuropathy were present. It is also the first in which typical multifocal motor neuropathy with conduction blocks spontaneously recovered without Ig.ev treatment and did not reappear over a long follow-up period. In our opinion, this strengthens the hypothesis of an actual adverse effect of infliximab in this patient. Finally, our case is the first one occurring in a patient with ankylosing spondylitis.
Paolazzi
Giuseppe
G
Department of Rheumatology, S. Chiara Hospital, Trento, Italy.
Peccatori
Susanna
S
Cavatorta
Francesco P
FP
Morini
Alberto
A
D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D004576:Electromyography; D006801:Humans; D000069285:Infliximab; D008297:Male; D008875:Middle Aged; D011129:Polyradiculoneuropathy / Q000139:chemically induced*; D012075:Remission, Spontaneous; D013167:Spondylitis, Ankylosing / Q000188:drug therapy*; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
D000911:Antibodies, Monoclonal; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab